Neuberger Berman Group
TVGN icon

Neuberger Berman Group’s Tevogen Bio Holdings TVGN Stock Holding History

Neuberger Berman Group’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-288
Closed -$4.76K – 2263
2025
Q4 		$4.76K Buy
+288
New +$7.49K ﹤0.01% 2108

Other funds holding TVGN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Neuberger Berman Group's TVGN Position: Q1 2026 in Review

Neuberger Berman Group sold out of Tevogen Bio Holdings (TVGN) in Q1 2026, closing a stake of 288 shares — an estimated $4.76K sold.

Neuberger Berman Group first reported a position in TVGN in Q4 2025 and held it in 1 quarter. The position peaked at $4.76K in Q4 2025. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

  • Neuberger Berman Group reported no remaining Tevogen Bio Holdings position as of Q1 2026 after selling out during the quarter.
  • Neuberger Berman Group sold 288 Tevogen Bio Holdings shares in Q1 2026, an estimated $4.76K.
  • Neuberger Berman Group first reported a position in Tevogen Bio Holdings in Q4 2025 and held it in 1 quarter.
  • Neuberger Berman Group's Tevogen Bio Holdings position peaked at $4.76K in Q4 2025.
  • 30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.